HIGH SPRINGS, FL--(Marketwire - December 22, 2009) - CTD Holdings, Inc. (OTCBB: CTDH)
(FRANKFURT: CDJ) announced today that the Company has entered into a Letter
of Intent to form a Joint Venture with J. Jireh Holdings, LLC.
Under the agreement CTD Holdings will contribute cash and other assets to a
joint venture (JV) with J. Jireh which will contribute know how and other
assets. The JV will develop and manufacture proprietary cyclodextrin
complexes and branded products utilizing joint intellectual contributions
and the pulse combustion dryer purchased by the JV. The physical plant is
located and operating in Payson, Arizona.
"This joint venture will combine over $1.0 million dollars of intellectual,
physical and cash assets to develop and manufacture branded cyclodextrin
complexes and products," stated C.E. "Rick" Strattan, Chief Executive
Officer of CTD Holdings, Inc. Mr. Strattan further stated, "We believe that
by combining pulse combustion drying techniques unique to J. Jireh, the CD
innovations of CTD and the pulse drying expertise of Dr. Jeff Tate, the new
joint venture, to be called NanoSonic, Products, Inc., will quickly develop
products enhanced by complexation with the right CD. Our first products
will focus on the nutraceutical and alternative energy industries."
Jeffrey Tate PhD, will join the JV as Chief Operating Officer and
President. Mr. Strattan will be the Chief Executive Officer of the JV.
ViStra Growth Partners, Inc., a wholly owned subsidiary of CTD Holdings,
was an integral part of the corporate structure, negotiating and assembly
of the documents necessary to affect the Letter of Intent. Mr. Louis
Weltman, CEO of ViStra stated, "We are confident that our contribution to
this strategic alliance will assist CTD in its efforts to more fully
develop its potential as an innovator, manufacturer and developer of
cyclodextrin complexes."
About CTD Holdings, Inc.
The company is the one-stop shop, business-to-business facilitator of
commercial and research applications of Cyclodextrins. With its branded
Trappsol®, Aquaplex® and Cyclo™ product offerings, CTDH scientists
coordinate the development of commercial products for use in the
pharmaceuticals, foods, hazardous waste treatment, and cosmetics
industries, which endeavor to put non water-soluble ingredients into
water-based formulations. More recently CTDH has worked, in an advisory
capacity, on the benefits and application of Cyclodextrins as a treatment
for Niemann Pick C disease, a debilitating childhood disease often called
Childhood Alzheimer's. More information about the company is available on
the company's website: www.cyclodex.com
This news release contains "forward-looking statements" that are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. You are cautioned that such statements are subject to
risks and uncertainties that could cause future circumstances, events or
results to differ materially from those projected in the forward-looking
statements. CTDH complies with the regulations and time lines mandated by
the SEC in the filing of its financial reports; these filings also contain
forward-looking statements. The above forward-looking statements are made
as of the date above; CTD Holdings, Inc. accepts no specific responsibility
for updating such statements.
